Suppr超能文献

补偿适应性代价和抗生素耐药性突变的可逆性。

Compensation of fitness costs and reversibility of antibiotic resistance mutations.

机构信息

Theoretical Biology, Institute of Integrative Biology, ETH Zürich, Zürich, Switzerland.

出版信息

Antimicrob Agents Chemother. 2010 May;54(5):2085-95. doi: 10.1128/AAC.01460-09. Epub 2010 Feb 22.

Abstract

Strains of bacterial pathogens that have acquired mutations conferring antibiotic resistance often have a lower growth rate and are less invasive or transmissible initially than their susceptible counterparts. However, fitness costs of resistance mutations can be ameliorated by secondary site mutations. These so-called compensatory mutations may restore fitness in the absence and/or presence of antimicrobials. We review literature data and show that the fitness gains in the absence and presence of antibiotic treatment need not be correlated. The aim of this study is to gain a better conceptual grasp of how compensatory mutations with different fitness gains affect evolutionary trajectories, in particular reversibility. To this end, we developed a theoretical model with which we consider both a resistance and a compensation locus. We propose an intuitively understandable parameterization for the fitness values of the four resulting genotypes (wild type, resistance mutation only, compensatory mutation only, and both mutations) in the absence and presence of treatment. The differential fitness gains, together with the turnover rate and the mutation rate, strongly affected the success of antibacterial treatment, reversibility, and long-term abundance of resistant strains. We therefore propose that experimental studies of compensatory mutations should include fitness measurements of all possible genotypes in both the absence and presence of an antibiotic.

摘要

具有赋予抗生素抗性突变的细菌病原体菌株的生长速度通常比其敏感株最初更低,侵袭性或传染性更低。然而,耐药性突变的适应性成本可以通过次要部位的突变得到缓解。这些所谓的补偿性突变可以在没有和/或存在抗生素的情况下恢复适应性。我们回顾了文献数据,表明在没有和存在抗生素治疗的情况下适应性增益不一定相关。本研究的目的是更好地理解具有不同适应性增益的补偿性突变如何影响进化轨迹,特别是可逆转性。为此,我们开发了一个理论模型,其中我们同时考虑了一个耐药性和一个补偿性基因座。我们提出了一种直观的参数化方法,用于在没有和存在治疗的情况下,对四种可能基因型(野生型、仅耐药突变、仅补偿突变以及两种突变)的适应性值进行建模。在不同的适应性增益、周转率和突变率的共同作用下,对抗菌治疗的成功率、可逆转性和耐药菌株的长期丰度产生了强烈影响。因此,我们建议,对补偿性突变的实验研究应包括在没有和存在抗生素的情况下所有可能基因型的适应性测量。

相似文献

1
Compensation of fitness costs and reversibility of antibiotic resistance mutations.
Antimicrob Agents Chemother. 2010 May;54(5):2085-95. doi: 10.1128/AAC.01460-09. Epub 2010 Feb 22.
2
Predictable properties of fitness landscapes induced by adaptational tradeoffs.
Elife. 2020 May 19;9:e55155. doi: 10.7554/eLife.55155.
3
The cost of antibiotic resistance depends on evolutionary history in Escherichia coli.
BMC Evol Biol. 2013 Aug 2;13:163. doi: 10.1186/1471-2148-13-163.
4
Hypermutability and compensatory adaptation in antibiotic-resistant bacteria.
Am Nat. 2010 Sep;176(3):303-11. doi: 10.1086/655217.
5
Multidrug-resistant bacteria compensate for the epistasis between resistances.
PLoS Biol. 2017 Apr 18;15(4):e2001741. doi: 10.1371/journal.pbio.2001741. eCollection 2017 Apr.
6
Epidemiological control of drug resistance and compensatory mutation under resistance testing and second-line therapy.
Epidemics. 2013 Dec;5(4):164-73. doi: 10.1016/j.epidem.2013.08.002. Epub 2013 Sep 4.
7
Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium.
Mol Microbiol. 2002 Oct;46(2):355-66. doi: 10.1046/j.1365-2958.2002.03173.x.
9
Genotype-by-environment interactions due to antibiotic resistance and adaptation in Escherichia coli.
J Evol Biol. 2013 Aug;26(8):1655-64. doi: 10.1111/jeb.12172. Epub 2013 May 23.
10
Fitness Costs of Antibiotic Resistance Impede the Evolution of Resistance to Other Antibiotics.
ACS Infect Dis. 2023 Oct 13;9(10):1834-1845. doi: 10.1021/acsinfecdis.3c00156. Epub 2023 Sep 19.

引用本文的文献

1
Core Perturbomes of and Using a Machine Learning Approach.
Pathogens. 2025 Aug 7;14(8):788. doi: 10.3390/pathogens14080788.
2
The diverse phenotypic and mutational landscape induced by fluoroquinolone treatment.
mSystems. 2025 Aug 19;10(8):e0071325. doi: 10.1128/msystems.00713-25. Epub 2025 Jul 31.
3
Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs.
Proc Natl Acad Sci U S A. 2025 Apr 15;122(15):e2422520122. doi: 10.1073/pnas.2422520122. Epub 2025 Apr 11.
4
Fluoroquinolone-specific resistance trajectories in E. coli and their dependence on the SOS-response.
BMC Microbiol. 2025 Jan 21;25(1):37. doi: 10.1186/s12866-025-03771-5.
5
An eco-evolutionary perspective on antimicrobial resistance in the context of One Health.
iScience. 2024 Dec 5;28(1):111534. doi: 10.1016/j.isci.2024.111534. eCollection 2025 Jan 17.
6
The emergence of nonlinear evolutionary trade-offs and the maintenance of genetic polymorphisms.
Biol Lett. 2024 Dec;20(12):20240296. doi: 10.1098/rsbl.2024.0296. Epub 2024 Dec 4.
7
Context-dependent fitness benefits of antibiotic resistance mutations.
Proc Biol Sci. 2024 Aug;291(2027):20241071. doi: 10.1098/rspb.2024.1071. Epub 2024 Jul 24.
8
Comparative fitness trade-offs associated with azole resistance in clinical isolates.
Heliyon. 2024 Jun 4;10(12):e32386. doi: 10.1016/j.heliyon.2024.e32386. eCollection 2024 Jun 30.
9
Upregulated Palmitoleate and Oleate Production in Promotes Gentamicin Resistance.
Molecules. 2024 May 25;29(11):2504. doi: 10.3390/molecules29112504.
10
The Emergence of Non-Linear Evolutionary Trade-offs and the Maintenance of Genetic Polymorphisms.
bioRxiv. 2024 Jun 1:2024.05.29.595890. doi: 10.1101/2024.05.29.595890.

本文引用的文献

1
Functional characterization of the antibiotic resistance reservoir in the human microflora.
Science. 2009 Aug 28;325(5944):1128-1131. doi: 10.1126/science.1176950.
2
Interplay in the selection of fluoroquinolone resistance and bacterial fitness.
PLoS Pathog. 2009 Aug;5(8):e1000541. doi: 10.1371/journal.ppat.1000541. Epub 2009 Aug 7.
3
VanA-type vancomycin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2009 Nov;53(11):4580-7. doi: 10.1128/AAC.00346-09. Epub 2009 Jun 8.
4
Drug interactions and the evolution of antibiotic resistance.
Nat Rev Microbiol. 2009 Jun;7(6):460-6. doi: 10.1038/nrmicro2133.
5
VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin.
Antimicrob Agents Chemother. 2009 May;53(5):1974-82. doi: 10.1128/AAC.00034-09. Epub 2009 Mar 9.
6
Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 May;53(5):1983-6. doi: 10.1128/AAC.01535-08. Epub 2009 Mar 9.
7
Functional relationship between bacterial cell density and the efficacy of antibiotics.
J Antimicrob Chemother. 2009 Apr;63(4):745-57. doi: 10.1093/jac/dkn554. Epub 2009 Feb 13.
8
Exploring the role of the immune response in preventing antibiotic resistance.
J Theor Biol. 2009 Feb 21;256(4):655-62. doi: 10.1016/j.jtbi.2008.10.025. Epub 2008 Nov 8.
10
Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis.
Microb Pathog. 2008 Nov-Dec;45(5-6):408-14. doi: 10.1016/j.micpath.2008.09.003. Epub 2008 Sep 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验